SPECIAL NOTICE
A -- DEVELOPMENT OF CRYOPRESERVATION COCKTAILS FOR THE STORAGE OF PERIPHERAL BLOOD MONONUCLEAR CELL AND WHOLE BLOOD SAMPLES
- Notice Date
- 5/9/2003
- Notice Type
- Special Notice
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bldg 427 Room 12, Frederick, MD, 21702
- ZIP Code
- 21702
- Solicitation Number
- Reference-Number-NCI-CRADA-01859
- Response Due
- 6/6/2003
- Archive Date
- 6/21/2003
- Point of Contact
- Jeffrey Thomas, Senior Advisor, Phone (301)846-5465, Fax (301)846-6820, - Jeffrey Thomas, Senior Advisor, Phone (301)846-5465, Fax (301)846-6820,
- E-Mail Address
-
jeffreyt@mail.nih.gov, jeffreyt@mail.nih.gov
- Description
- DEVELOPMENT OF CRYOPRESERVATION COCKTAILS FOR THE STORAGE OF PERIPHERAL BLOOD MONONUCLEAR CELL AND WHOLE BLOOD SAMPLES Pursuant to the Federal Technology Transfer Act (15 U.S.C. 3710 as amended), the National Cancer Institute (NCI) is currently seeking a partner under a Cooperative Research and Development Agreement (CRADA) to work with the NCI Division of Cancer Epidemiology and Genetics (DCEG) and the NCI-Frederick contractor's (SAIC-Frederick, Inc.) Applied/Developmental Research Support Program (ADRSP) to develop cryopreservation cocktails in an effort to create a more stable environment for Peripheral Blood Mononuclear Cell (PBMC) and whole blood samples in long-term or short-term storage. The NCI has an ongoing need to assure that its frozen repository samples are stored in a manner that assures their viability while also preserving the integrity of their phenotypic characteristics. Such sample integrity is essential to the ongoing cancer research efforts involving samples of this type. NCI'S CONTRIBUTIONS TO THE CRADA DCEG and ADRSP will: Design the CRADA research plan and establish sample requirements jointly with the CRADA collaborator; Assist in the design of cryopreservation cocktails; Provide sample processing and rate-controlled freezing to evaluate candidate cryopresevation cocktails; Perform phenotypic assays on samples frozen using candidate cocktails to determine characteristics such as viability, proliferation, cytokine production, cytotoxicity and recovery determination; Analyze data and publish the results jointly with the CRADA collaborator. COLLABORATOR CONTRIBUTIONS TO THE CRADA The CRADA collaborator will: Design the CRADA research plan and establish sample requirements jointly with DCEG and ADRSP; Have expertise to develop unique cryopreservation cocktails containing balanced salt concentrations, apoptotic inhibitors, and/or antioxidants that would be suitable for long and short-term storage of PBMC and whole blood samples pursuant to jointly established sample requirements. Candidate cocktails should contain no dimethylsulfoxide (DMSO) or minimal concentrations of DMSO; Have development and commercial rights to proprietary anti-oxidants or apoptotic inhibitors suitable for use in candidate cryopreservation cocktails developed under this CRADA; Have the means to produce pilot study amounts of candidate cryopreservation cocktails; Analyze data and publish the results jointly with DCEG and ADRSP. RESPONSE CRITERIA Interested parties should submit a brief Statement of Interest (two pages maximum) summarizing their qualifications, which must be received by June 6, 2003 at the address noted in the Contact Information section of this announcement. Parties determined to have the potential to fulfill the collaborator contributions to the proposed project based upon their Statement of Interest will be contacted regarding the next step in the selection process. The next step may include a more detailed proposal describing the potential collaborator's expertise and resources. If a collaborator is not selected from the initial responses received by the deadline, this CRADA opportunity may remain open for further responses from interested parties until a collaborator is selected. SELECTION CRITERIA The CRADA collaborator will be chosen according to the following criteria based upon evaluation of the Statements of Interest and more detailed proposals (if necessary): Technical and scientific expertise in the field of cryopreservation and in the development of cryopreservation reagents; Rights in proprietary apoptotic inhibitors and antioxidants for use in this CRADA and subsequent commercialization; Demonstration of adequate resources to perform the research and accomplish the objectives in a reasonable timetable; Demonstration of expertise in the commercial development, production, marketing and sales of cryopreservation reagents; The willingness to cooperate with the NCI in the timely publication of research results; The willingness to assist the NCI in its mission to make laboratory research tools available to the research community pursuant to the NIH Principles and Guidelines for Sharing of Biomedical Research Resources (http://ott.od.nih.gov/NewPages/pubs.html). CRADA TERM AND LICENSING OPTIONS The term of this CRADA is expected to be approximately two (2) years. No funding from the Government is available to the CRADA collaborator. Collaborator will receive a time-limited exclusive option to license Government solely-owned or the Government's share of jointly-owned Subject Inventions developed under the CRADA. The scope of any license granted to the CRADA collaborator will be commensurate with the scope of the CRADA research plan. CONTACT INFORMATION Statements of Interest or questions related to this CRADA opportunity should be submitted to: Jeffrey W. Thomas, Ph.D., NCI Technology Transfer Branch, 1003 W. 7th Street, Suite 500, Frederick, MD 21701; Phone: 301-846-5465; Fax: 301-846-6820; Email: jeffreyt@mail.nih.gov. Scientific inquiries should be directed to Mark Cosentino, Ph.D., Phone: 301-846-6543, Fax:301-846-6536, Email: mcosentino@ncifcrf.gov.
- Record
- SN00321122-W 20030511/030509213336 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |